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The inconsistent results on the effects of vitamin D on muscle strength reported by interven-
tion trials may partly be explained by inclusion of vitamin D sufficient individuals. The main
objective was to study whether vitamin D supplementation will improve muscle strength in
men and women with low serum vitamin D status, as measured by 25-hydroxyvitamin D (25
(OH)D) at baseline.
Methods
417 men and women aged 40–80 years were included and randomized to receive a loading
dose of 100 000 IU (2500 ug) vitamin D3 followed by 20 000 IU (500 ug)/week, or placebo.
Muscle strength was tested by dynamometers at baseline and after four months.
Results
Serum 25(OH)D levels increased from 32.6±11.1 nmol/l to 88.8±19.4 nmol/l (p<0.01) in the
vitamin D group, while remaining low in the placebo group (baseline and final levels at 35.1
±13.6 nmol/l and 30.7 ±9.7 nmol/l respectively). Muscle strength (hip flexion, biceps flexion,
pectorals and handgrip strength) did not change in any of the groups. The results were the
same in analyses stratified on sex, 25(OH)D above/below 25 nmol/L (10 ng/ml); smoking
status; and BMI above/below 27 kg/m2.
Conclusion
These data does not support vitamin D supplementation for improving muscle strength.
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Introduction
Vitamin D deficiency is common [1], and associated with numerous negative health outcomes
[2]. In particular, vitamin D is important for skeletal health, as deficiency may lead to rickets
or osteomalacia [3]. The effects of vitamin D on fractures and falls have recently been ques-
tioned [4].
Muscle weakness and pain are commonly seen in osteomalacia [5], vitamin D receptors are
present in muscle cells [6,7], and several observational studies have reported inverse associa-
tions between serum 25-hydroxyvitamin D (25(OH)D) levels and muscle strength [8,9]. Possi-
ble mechanisms include changes in muscle morphology (with atrophy of type 2 muscle fibers
[10] as well as increased fatty infiltration in skeletal muscle [11]), improved mitochondrial
function with vitamin D supplementation [12], and by optimizing contractility through regu-
lation of calcium and phosphate handling [13]. Taking these results into account, one could
expect an effect on muscle strength and function with vitamin D supplementation, but as the
results from randomized controlled trials (RCTs) have been inconsistent, meta-analyses have
concluded differently [14,15]. Thus, Beaudart et al. reported in 2014 in a systematic review and
meta-analysis of RCTs using vitamin D a small, but significant effect of vitamin D supplemen-
tation on global muscle strength, which was more evident in people with 25(OH)D < 30
nmol/l as well as in people� 65 years of age [14]. On the other hand, no effect was found in a
similar systematic review and meta-analyses by Rosenahl-Riise et al. in 2017 [15].
Some of the heterogeneity of the results may be a reflection of different study designs,
where a common pitfall is to include participants with sufficient vitamin D status (measured
as 25-hydroxyvitamin D (25(OH)D)) at baseline [16,17]. Another limitation of the available
studies, is that most of them are performed only with women [15].
We had the opportunity to include healthy community-dwelling participants of both gen-
ders and with low basal serum 25(OH)D levels from a large population-based study, in a ran-
domized controlled trial with vitamin D supplementation over four months, assessing changes
in standardized measurements of muscle strength. We hypothesized that vitamin D supple-




The Tromsø study is a population based health survey that was first conducted in 1974 [18].
In the seventh wave in 2015/2016, all citizens aged 40 years and older (n = 32 591) living in
the municipality of Tromsø in northern Norway were invited to participate, where 21 083
attended. Serum 25(OH)D was measured on an ongoing basis in a total of 20922 participants,
and based on the distribution, those with levels below the 7th percentile (<42 nmol/L (16.8
ng/ml)) and age<80 years were invited to participate in this study. Of 1489 subjects invited,
639 responded positively and were phone screened by the study nurses from the Clinical
Research Unit at the University Hospital of North Norway. A standardized medical interview
was performed in order to exclude subjects with known granulomatous disease, renal stones
last five years, or serious diseases apparent through interview or screening blood tests that
would make the subject unfit for participation. Patients with diabetes were excluded from par-
ticipation due to one of the primary outcomes insulin resistance. Additionally, subjects with
use of vitamin D supplements exceeding 800 IU (20 ug) vitamin D per day, subjects who used
solarium on a regular basis, or were planning holiday(s) in tropical areas during the study
period were excluded from participation. Women of childbearing potential (below the age of
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50 years) without use of contraception were excluded. Weight and height and smoking status
were asked for and used in the randomization procedure.
Study design
The main end point of the study was effects on cardio-vascular risk factors, and the study
design has been described in detail elsewhere [19]. In short, those who fulfilled the inclusion
criteria, came to the first visit at the Clinical Research Unit of the University Hospital of North
Norway for signing of the informed consent form, clinical examinations, height and weight
measurements wearing light clothing and no shoes, medical history and fasting blood samples
which included hemoglobin, liver enzymes, calcium, creatinine, thyroid hormones and TSH,
high-sensitive CRP, sedimentation rate and glycated hemoglobin. If these examinations did
not reveal any contraindication for participation, the next visit was performed within 2–5
days. At this second visit, the muscle strength testing was performed and the study drugs (20
000 IU (500 ug) cholecalciferol capsules Dekristol, Mibe, Jena, Germany) or identical looking
placebo capsules containing arachis oil (Hasco-Lek, Wroclaw, Poland) were dispensed. Five
capsules were given as a loading dose, followed by one capsule each week. The subjects were
asked not to take any vitamin D supplements (including cod liver oil) during the four months
intervention period.
The randomization was stratified according to gender, vitamin D status in the Tromsø
study (serum 25(OH)D above/below 25 nmol/L (10 ng/ml)), smoking status (current smoking
or not) and BMI above/below 27 kg/m2 (self-reported height and weight). Based on this, the
randomization unit assigned the subject a randomization number using a block randomiza-
tion procedure with random block sizes of 2, 4 or 6. This number was sent to the Clinical
Research Unit (who did not have the randomization key) and to the hospital’s pharmacy (who
had the key), with the latter dispensing the medication accordingly. Except for the pharmacy,
which had no contact with the study participants, all nurses, doctors, other study personnel
and study participants were blinded for the randomization throughout the study.
Two months after inclusion, a study nurse contacted the participants by phone to ask for
adverse events and remind them to take the study medication. At four months the third visit
was performed with examinations identical to the first visit. The fourth visit followed a few
days later, with return of study medication and examinations identical to the second visit.
Compliance was calculated as the ratio between capsules used (capsules supplied minus cap-
sules returned) and number of weeks between second and fourth visit.
Muscle strength testing
Handgrip strength was measured using a Jamar Plus dynamometer (Jamar Technologies,
Lakewood, NJ, USA). The dominant side was used, but if there was a known injury or func-
tional loss in the dominant side, the non-dominant side was preferred, also for the repeated
final examination. Hip flexion strength, pectoralis strength and biceps strength were measured
by use of the hand-held dynamometer Jtech Commander Muscle Tester (Jtech Medical Indus-
tries, Midvale, Utah, USA). Use of hand-held dynamometry have been shown to be a reliable
and valid instrument for muscle strength testing as compared to the gold standard isokinetic
dynamometry [20]. Standardized procedures were followed, with detailed description of how
to place and stabilize the patient in order to isolate the muscle group being tested. External
belt-fixation was used for hip and elbow flexion in order to avoid impact from the strength of
the research nurse [21]. The participants were carefully instructed how to perform the tests.
The participant was asked to press maximally towards the fixed dynamometer for three sec-
onds. The study nurse counted 1-2-3 before starting, and also told the participant when to
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stop. Each test was performed three times with 30 seconds rest in-between, and the highest of
the three measurements was used in the analyses.
Laboratory measurements
Serum 25(OH)D was measured by an in-house developed liquid chromatography–tandem
mass spectrometry method that detects both 25(OH)D3 and 25(OH)D2, as well as the sum of
these presented as 25(OH)D in the results [22]. The laboratory takes part in the external qual-
ity program DEQAS. Plasma parathyroid hormone (PTH) was analyzed with an electrochemi-
lumniscence immunoassay (ECLIA) using an automated clinical chemistry analyzer (Cobas
6000, Roche) with a reference range of 1.1–6.8 pmol/L for those <50 years and 1.1–7.5 pmol/L
for those >50 years. Serum calcium was analyzed by an automated analyzer (Modular P,
Roche Diagnostics, Mannheim, Germany).
Statistical methods and power calculation
We used the statistical software package SPSS version 22. Descriptive results are shown as
mean±SD if not stated otherwise. Normal distribution was evaluated by visual inspection
of plots, and although there was some skewness and curtosis present, parametric tests were
considered appropriate due to the large sample size. The end points were changes in muscle
strength (delta strength) between the beginning and the end of the study (second and fourth
visit), which was calculated separately for each participant. Independent t-tests were used for
between-groups comparisons of delta strength for biceps, hip flexion, hand grip and pectoralis,
as well as serum 25(OH)D, calcium and plasma PTH. Sensitivity analyses were performed in
strata according to the randomization factors gender; vitamin D status in the Tromsø study
(serum 25(OH)D above/below 25 nmol/L (10 ng/ml)); smoking status; and BMI above/below
27 kg/m2.
The power was calculated based on the main end point of the study, cardiovascular risk
factors. The effect of vitamin D supplementation was assumed to be about two-third of the
observed difference in cross-sectional studies between people with serum 25(OH)D levels of
30 and 80 nmol/l. Accordingly, between 300 and 500 participants were needed to attain a
power of 0.8 and p<0.05 to detect a difference of 6.7 mmHg in systolic blood pressure, 3.3
mmHg in diastolic pressure, 0.26 mmol/l in triglycerides, 0.09 mmol/l in HDL-cholesterol and
0.57 in HOMA-IR. To account for an assumed drop-put rate of 16%, the aim was to include
600 subjects [19].
Ethics
The study was approved by the Regional Committee for Medical Research Ethics (REK NORD
2013/1464) 4th of September 2014 and by the Norwegian Medicines Agency (2013-003514-40).
The study is registered at ClinicalTrials.gov NCT02750293. Due to a misunderstanding the
study was registered there shortly after the first subject was included. The authors confirm that
all ongoing and related trials for this drug/intervention are registered. The inclusion started
2nd of June 2015, and last visit was performed 27th of April 2017. All subjects gave their written
informed consent.
Results
Of the 639 participants screened by phone, 455 attended the first visit with clinical examina-
tion and blood sampling. Thirty-three participants did not fulfill the inclusion criteria, and
consequently 422 met to the second visit, and were randomized to vitamin D or placebo, one
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without successfully performed muscle testing. During the study, three participants withdrew
their consent, and seven were excluded due to intercurrent disease or medication use not
suitable with continuation. Thus, 411 completed the study and were included in the present
analyses (Fig 1). Their baseline characteristics are presented in Table 1. Those randomized to
vitamin D had a slightly lower 25(OH)D at baseline. Delta values for muscle strength, 25(OH)
Fig 1. Flow chart of the inclusion of participants.
https://doi.org/10.1371/journal.pone.0225600.g001
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D, PTH and calcium levels are shown in Table 2 and compared between the treatment groups.
Serum 25(OH)D increased significantly, accompanied by a significant decrease in PTH and a
slight increase in serum calcium in the vitamin D group as compared to the placebo group.
However, changes in muscle strength did not differ significant between the groups. The results
for changes in muscle strength were the same in the sensitivity analyses in strata of gender;
vitamin D; smoking status; and BMI as shown in Table 3.
The compliance to the study medication regimen was 100% in 86% of the participants, and
above 84% in all. No serious study-related side effects were recorded. Two participants devel-
oped slight hypercalcemia; one male whose serum calcium normalized upon retesting, and
one female who had developed primary hyperparathyroidism.
Discussion
In this randomized controlled trial including adults with low serum 25(OH)D levels, no effects
on muscular strength were observed after four months administration of vitamin D versus pla-
cebo. There were no gender differences.






Age (years) 51.5±8.6 52.6±8.7
Females (percentage) 46.6 46.8
BMI (kg/m2) 27.9±5.1 27.8±4.7
Serum 25(OH)D (nmol/L)� 32.6±11.1 35.1±13.6
Plasma PTH (pmol/L) 6.7±2.2 6.8±1.9
Serum calcium (mmol/L) 2.27±0.07 2.27±0.07
Smokers (percentage) 22.1 22.2
Hip flexion (N) 181.2±63.8 175.0±61.8
Biceps flexion (N) 129.5±66.8 129.4±66.8
Pectoralis (N) 307.7±137.3 306.0±138.5
Hand grip (kg) 41.8±11.6 41.9±12.7
N; Newton
Data are mean±SD if not stated otherwise.
�P for difference <0.05
https://doi.org/10.1371/journal.pone.0225600.t001





P for difference in change
between groups
n Change n Change
Hip flexion (N) 206 -0.6±49.9 198 -2.8±42.3 0.64
Biceps flexion (N) 206 5.2±49.3 198 1.2±51.1 0.43
Pectoralis (N) 205 18.4±83.4 197 11.9±82.6 0.43
Hand grip (kg) 206 1.0±4.2 199 0.5±4.3 0.31
25(OH)D (nmol/L) 208 56.2±22.2 203 -4.5±12.8 <0.01
Plasma PTH (pmol/L) 208 -0.8±1.4 203 0.5±1.5 <0.01
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These results are in contrast to a meta-analysis and review from 2014 concluding with a
weak, but positive, effect on muscle strength with vitamin D supplementation [14]. The effect
was only evident in persons aged 65 years or older, and the discrepancy with our results may
therefore be explained by inclusion of younger persons in our study, with few participants >65
years of age (<10%). The expression of VDRs in muscle is reported to decrease with age [7],
and therefore older people might be more vulnerable to vitamin D insufficiency. In a paper
published after the meta-analysis, a risk reduction of nearly 50% for injurious falls needing
medical attention was reported in a two year follow-up period after a two years intervention
trial with vitamin D in older women [23]. However, in a recent nine months vitamin D inter-
vention trial in older men with baseline 25(OH)D levels >60 nmol/l, no effects on gait speed
or Short Physical Performance Battery were observed [24]. Another study found no effect on
handgrip strength or Timed Up and Go in elderly people after administration of 12000, 24000
or 48000 IU/month cholecalciferol, for one year [25]. However, there was no placebo group.
Table 3. Changes in muscular strength during intervention. Stratified analyses.
Vitamin D Placebo P for difference in change between
groups
Vitamin D Placebo P for difference in change between
groupsn change n change n change n change
Female Male





95 5.2±29.7 93 12.9
±36.0
0.11 111 5.1±61.5 105 -9.2±59.8 0.09







Hand grip (kg) 96 1.1±4.2 93 0.9±3.6 0.67 110 0.9±4.2 106 0.3±4.8 0.33
Serum 25(OH)D�25 nmol/l Serum 25(OH)D>25 nmol/l




0.51 160 0.2±64.0 154 -1.3±43.9 0.80
Biceps flexion
(N)
47 1.8±46.1 44 3.5±43.3 0.86 159 6.1±50.3 154 0.6±53.2 0.34
Pectoralis (N) 47 13.3
±98.1
45 3.0±91.0 0.60 158 19.9
±78.7
152 14.6±80.0 0.55
Hand grip (kg) 47 1.2±3.7 45 0.0±4.1 0.18 159 0.9±4.4 154 0.7±4.4 0.63
Non-smokers Smokers





















Hand grip (kg) 161 0.9±4.2 156 0.6±4.3 0.67 45 1.4±4.2 43 0.2±4.4 0.17
BMI<27 kg/m3 BMI�27kg/m3
Hip flexion (N) 99 -3.1
±78.1
96 0.7±46.9 0.68 105 2.6±44.0 102 -6.1±37.3 0.13
Biceps flexion
(N)
99 6.1±52.1 93 1.4±52.5 0.53 105 4.5±47.3 105 1.1±50.1 0.61
Pectoralis (N) 99 12.0
±92.7
92 9.1±78.5 0.82 104 24.3
±74.2
105 14.4±86.3 0.38
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Finally, unfavorable effects on muscle strength were reported in elderly women randomized
to receive 2800 IU/day cholecalciferol as compared to placebo for three months in a Danish
study [26].
Several studies show that an effect of vitamin D supplementation on muscle strength is evi-
dent only in persons with serum 25(OH)D <30 nmol/l [14,27]. In contrast, we did not observe
any effects in our subgroup of participants with baseline levels below a similar threshold (25
nmol/l), which is in accordance with another recently published meta-analysis which reported
stronger effects of vitamin D supplementation on handgrip strength after exclusion of three
studies with low baseline 25(OH)D levels. The authors speculated that the low levels repre-
sented patients with a higher degree of frailty, where it was too late to improve muscle strength
[15]. In our study, the participants were community-dwelling, middle-aged people, recruited
through a health survey, which are generally prone to healthy user bias. Also, only ten of the
participants had sarcopenia as defined as maximal grip strength < 20 kg for women and 30 kg
for men at baseline [28]. We therefore find it unlikely that the lack of effect could be explained
by our participants being too frail to improve their muscle strength.
The effects of vitamin D may be dependent on interplay with factors like other conutrients
[16], in particular calcium intake. Unfortunately, we did not have information regarding diet
and calcium intake, but in general, the calcium intake in Scandinavian countries is high [29],
and it might be that the threshold for clinical vitamin D deficiency is shifted downwards in
such circumstances [30]. Also, some studies suggest that physical activity may interact with the
effects of vitamin D on muscle function [31]. Unfortunately, we do not have available data of
physical activity in our participants.
The heterogeneity in results between different studies and meta-analyses may at least to
some part reflect differences in study design. It has been speculated on whether the dosing reg-
imens might be of importance. Daily dosing has been argued to provide a more stable supply
of cholecalciferol, and could act more physiologically than bolus dosing on a weekly or even
more seldom basis, like used in the present study [32]. Another limitation of the present study
could be that the duration of the intervention was only four months, and a longer duration
may have been necessary to reveal any effects. However, for ethical reasons, it is challenging to
perform long term studies including placebo groups in participants with documented vitamin
D deficiency at baseline.
Also, we only measured one aspect of muscular function, namely strength, whereas endur-
ance, power and balance were not assessed. We did, however, measure both the upper- and
lower extremities, and included both proximal and distal strength. Still, it may be that we did
not capture functional strength. For instance, one study among Brazilian postmenopausal
women reported significant improvement in chair rising test, but no effect on handgrip
strength [33].
Recently, it has been suggested that circulating levels of 1,25 dihydroxyvitamin D (1,25
(OH)2D) might correlate better with muscle strength than 25(OH)D [34]. In a randomized six
months trial both treatments resulted in muscle strength improvements, but administration
of alphacalcidiol was significantly more effective than cholecalciferol [35]. It may therefore be
that this metabolite should be taken into account. However, we did not have 1,25(OH)2D mea-
surements available.
Finally, there were broad standard deviations in the changes in muscle strength in the treat-
ment groups which limit the possibility of finding a significant difference in this medium-
sized study. However, there were no trends in the results suggesting that this should explain
the lack of effect of vitamin D.
The study also has several strengths. First, both 25(OH)D and outcomes were measured by
validated methods. The participants were included based on low serum 25(OH)D
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measurements. The adherence to the study and the compliance rate were high, as confirmed
by the substantially increase in 25(OH)D levels in the intervention group.
To summarize, our results do not support an effect of vitamin D on muscular strength.
Future studies should consider using daily dosing, including assessment of conutrient status
and physical activity, and exploring use of active vitamin D in order to achieve a greater under-
standing of the vitamin D metabolism and musculoskeletal health.
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